Multi-gene testing is the quantitative testing of several genes associated with breast cancer, and the results are translated into a score by a specific algorithm to determine the risk of recurrence, which is one of the bases for doctors to choose a treatment.
However, multigene testing must be performed after routine estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER-2) testing, and is currently used only for hormone receptor-positive, HER-2-negative, lymph node-negative breast cancer patients, which can save this group of breast cancer patients from unnecessary overtreatment and allow for more accurate and effective diagnosis and treatment. However, if multiple gene testing is blindly performed on all breast cancer patients, it will instead increase the financial burden on patients.